Overview

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Status:
Completed
Trial end date:
2018-01-16
Target enrollment:
Participant gender:
Summary
Single center, prospective open label PK and PD study of betrixaban in subjects with mild and moderate hepatic impairment vs healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Portola Pharmaceuticals
Treatments:
Betrixaban